TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8365592

Group type: EXPERIMENTAL
Intervention: Diminutive adenoma group (66 subjects)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Mixed hyperplastic-adenomatous polyp group (12 subjects)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Hyperplastic polyp group (42 subjects)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control group (42 subjects)
Number of subjects: 162
Study: 3812057

Group type: EXPERIMENTAL
Intervention: basic treatment plus significant other support condition
Number of subjects: 29

Group type: COMPARATOR
Intervention: basic smoking control program
Number of subjects: 29
Study: 29870867

Group type: EXPERIMENTAL
Intervention: SPIRIT in-person
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: SPIRIT remote
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: SPIRIT
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 120
Study: 26746907

Group type: EXPERIMENTAL
Intervention: Motion control shoes
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Motion control shoes (in runners with pronated feet)
Number of subjects: 372

Group type: COMPARATOR
Intervention: Standard shoes (in runners with pronated feet)
Number of subjects: 372

Group type: COMPARATOR
Intervention: Standard shoes (in runners with neutral feet)
Number of subjects: 372

Group type: COMPARATOR
Intervention: Standard shoes (in runners with supinated feet)
Number of subjects: 372
Study: 25710636

Group type: EXPERIMENTAL
Intervention: Exercise (submaximal invasive cardiopulmonary exercise test)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (submaximal invasive cardiopulmonary exercise test)
Number of subjects: 17
Study: 23897911

Group type: EXPERIMENTAL
Intervention: Single nasal prong (SNP)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Face mask (FM)
Number of subjects: 144
Study: 20667535

Group type: EXPERIMENTAL
Intervention: Testosterone (testosterone undecanoate, 40 mg/day)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Estrogen (oral E2 2 mg/day)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 19032397

Group type: EXPERIMENTAL
Intervention: 39 Gy in 13 fractions
Number of subjects: 92

Group type: COMPARATOR
Intervention: 17 Gy in two fractions
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Decision-making process involvement
Number of subjects: 92
Study: 17012443

Group type: EXPERIMENTAL
Intervention: 12-hour magnesium sulfate (MgSO4) therapy
Number of subjects: 200

Group type: COMPARATOR
Intervention: 24-hour magnesium sulfate (MgSO4) therapy
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both 12-hour and 24-hour magnesium sulfate (MgSO4) therapy
Number of subjects: 200
Study: 14592583

Group type: EXPERIMENTAL
Intervention: Ultrasound assessment with AFI <5 cm
Number of subjects: 1584

Group type: EXPERIMENTAL
Intervention: Ultrasound assessment with single deepest pool <2 cm
Number of subjects: 1584

Group type: EXPERIMENTAL
Intervention: AFI <5 cm
Number of subjects: 1584
Study: 11078487

Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg once daily
Number of subjects: 668

Group type: COMPARATOR
Intervention: Tamoxifen 20 mg once daily
Number of subjects: 668
Study: 8818376

Group type: EXPERIMENTAL
Intervention: Present State Examination (PSE) at baseline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Present State Examination (PSE) at follow up
Number of subjects: 0
Study: 1330942

Group type: COMPARATOR
Intervention: Placebo (oral administration)
Number of subjects: 16
Study: 29545325

Group type: EXPERIMENTAL
Intervention: Patient-reported safety concerns
Number of subjects: 2471

Group type: EXPERIMENTAL
Intervention: Patient-reported safety incidents
Number of subjects: 2471

Group type: EXPERIMENTAL
Intervention: Classification of patient-reported safety concerns
Number of subjects: 2471
Study: 27270968

Group type: EXPERIMENTAL
Intervention: Prucalopride (2 mg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: PEG3350 (2 × 13.8 g)
Number of subjects: 13
Study: 24841020

Group type: COMPARATOR
Intervention: Caudal block with 1 ml/kg bupivacaine 0.25% combined with 1 μg/kg clonidine
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Ilioinguinal-iliohypogastric nerve block with 0.3 ml/kg bupivacaine 0.25% combined with 1 μg/kg clonidine
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 67
Study: 23545284

Group type: EXPERIMENTAL
Intervention: CVI of 5‐Fluorouracil (5‐FU), 225 mg/m(2) per day, 7 days per week plus pelvic hyperfractionated radiation (HRT), 45.6 Gy at 1.2 Gy twice daily plus a boost of 9.6 to 14.4 Gy for T3 or T4 cancers (Arm 1)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: CVI of 5‐FU, 225 mg/m(2) per day, Monday to Friday, plus irinotecan, 50 mg/m(2) once weekly × 4, plus pelvic radiation therapy (RT), 45 Gy at 1.8 Gy per day and a boost of 5.4 Gy for T3 and 9 Gy for T4 cancers (Arm 2)
Number of subjects: 106
Study: 20004739

Group type: EXPERIMENTAL
Intervention: Parenteral nutrition designed to provide 100% of measured resting energy expenditure (REE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard parenteral nutrition (140% of estimated energy expenditure)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parenteral nutrition designed to provide 100% of measured REE
Number of subjects: 0
Study: 18262380

Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment using sulfadoxine‐pyrimethamine
Number of subjects: 648

Group type: COMPARATOR
Intervention: Weekly chemoprophylaxis with chloroquine
Number of subjects: 648

Group type: COMPARATOR
Intervention: Intermittent preventive treatment using three doses of chloroquine
Number of subjects: 648
Study: 16573311

Group type: EXPERIMENTAL
Intervention: Duloxetine (40-120 mg/day)
Number of subjects: 817

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 817
Study: 12798153

Group type: EXPERIMENTAL
Intervention: Cervitec (1% chlorhexidine + 0.1% thymol) applied three times over 2 weeks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: EC40 (40% chlorhexidine) applied once or twice over 2 weeks
Number of subjects: 24
Study: 10900675

Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (ERT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conjugated estrogens and combined progestin treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estrogen
Number of subjects: 0
Study: 8829403

Group type: EXPERIMENTAL
Intervention: 0.5% lidocaine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 1% lidocaine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 2% lidocaine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 5% lidocaine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 10% lidocaine
Number of subjects: 40
Study: 1503446

Group type: COMPARATOR
Intervention: Cipro alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Calcium carbonate (4 x 850 mg tablets taken 5 min before Cipro)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide (3 x 600 mg tablets taken 5 min before Cipro)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide
Number of subjects: 12
Study: 6147695

Group type: EXPERIMENTAL
Intervention: Breathing retraining followed by 7 weekly sessions of real-life exposure
Number of subjects: 12

Group type: COMPARATOR
Intervention: Real-life exposure without breathing retraining
Number of subjects: 12
Study: 31497673

Group type: EXPERIMENTAL
Intervention: Usual letter
Number of subjects: 4500

Group type: EXPERIMENTAL
Intervention: Nudge-based letter
Number of subjects: 4500

Group type: COMPARATOR
Intervention: Conventional follow-up (Control)
Number of subjects: 4500
Study: 29508273

Group type: EXPERIMENTAL
Intervention: Staple line reinforcement (SLR) using unidirectional absorbable 3/0 V‐Loc 180 sutures
Number of subjects: 920

Group type: COMPARATOR
Intervention: No staple line reinforcement (Control group)
Number of subjects: 920
Study: 26851698

Group type: EXPERIMENTAL
Intervention: Oxytocin (40 IU)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 24613367

Group type: EXPERIMENTAL
Intervention: Intravenous iron administration (510 mg elemental iron as ferumoxytol)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 39
Study: 22617226

Group type: EXPERIMENTAL
Intervention: Rifampicin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 0
Study: 20398947

Group type: EXPERIMENTAL
Intervention: Speech therapy with soft palate phonemes (Group I, N=20)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Speech therapy with lips and gingival phonemes (Group II, N=20)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Medical therapy only (Group III, N=10)
Number of subjects: 50
Study: 16995844

Group type: EXPERIMENTAL
Intervention: PVP extract
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 12783039

Group type: EXPERIMENTAL
Intervention: Creatine (CRT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 22
Study: 11125604

Group type: EXPERIMENTAL
Intervention: Comprehensive NPO instructions (experimental group, n = 66)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Usual NPO instructions (control group, n = 56)
Number of subjects: 122
Study: 9329204

Group type: EXPERIMENTAL
Intervention: Marked target condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unmarked target condition
Number of subjects: 0
Study: 7693422

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 100 mg/m2 orally on days 1 to 14, Methotrexate 40 mg/m2 intravenously on days 1 and 8, Fluorouracil 600 mg/m2 intravenously on days 1 and 8 every 4 weeks for 6 cycles (CMF)
Number of subjects: 761

Group type: COMPARATOR
Intervention: Fluorouracil 600 mg/m2, Epirubicin 50 mg/m2, Cyclophosphamide 600 mg/m2 (FEC), all given intravenously on day 1 for 8 cycles at 3-week intervals
Number of subjects: 761
Study: 3517228

Group type: EXPERIMENTAL
Intervention: Long-acting propranolol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31774511

Group type: EXPERIMENTAL
Intervention: Exposure to community health entrepreneurship
Number of subjects: 1211
Study: 27215840

Group type: EXPERIMENTAL
Intervention: Taste Lessons with additional experiential learning activities (TLVM)
Number of subjects: 877

Group type: EXPERIMENTAL
Intervention: Taste Lessons (TL)
Number of subjects: 877

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 877
Study: 25926506

Group type: EXPERIMENTAL
Intervention: Phenylalanine supplementation (5-177 mg/kg per day) as part of an elemental formula
Number of subjects: 36
Study: 23566267

Group type: EXPERIMENTAL
Intervention: Local methylcobalamin injection
Number of subjects: 98

Group type: COMPARATOR
Intervention: Oral methylcobalamin
Number of subjects: 98

Group type: COMPARATOR
Intervention: Subcutaneous 1.0% lidocaine injection
Number of subjects: 98
Study: 21307037

Group type: EXPERIMENTAL
Intervention: Pharmacoinvasive therapy (early routine PCI)
Number of subjects: 1059

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 1059
Study: 19098852

Group type: EXPERIMENTAL
Intervention: Extended treatment with peginterferon plus ribavirin for 48-68 weeks (44 weeks after HCV RNA negative)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Standard treatment with peginterferon plus ribavirin for 48 weeks
Number of subjects: 113
Study: 16835600

Group type: EXPERIMENTAL
Intervention: Iron supplementation (30 mg elemental iron as ferrous sulfate daily for 6 weeks)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 15915396

Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) epinephrine
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) epinephrine
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control (H1 and H2 receptor blockade)
Number of subjects: 63
Study: 12503018

Group type: EXPERIMENTAL
Intervention: Flexible bioabsorbable cement restrictor with decompression valves
Number of subjects: 108

Group type: COMPARATOR
Intervention: General anesthesia without oxygen enrichment
Number of subjects: 108

Group type: COMPARATOR
Intervention: Spinal anesthesia with optional oxygen delivery
Number of subjects: 108
Study: 11382873

Group type: EXPERIMENTAL
Intervention: Narcolepsy-cataplexy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Habitual nappers
Number of subjects: 0
Study: 7899535

Group type: EXPERIMENTAL
Intervention: L-5-hydroxytryptophan (L-5-HTP, 200 mg PO)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Dexamethasone (1 mg PO)
Number of subjects: 47
Study: 2672773

Group type: EXPERIMENTAL
Intervention: High-fat, low-carbohydrate diet (39% fat, P:S ratio 0.30 or 1.00)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Low-fat, high-carbohydrate diet (19% fat, same P:S ratio)
Number of subjects: 31
Study: 857761

Group type: EXPERIMENTAL
Intervention: High epidural analgesia (bupivacaine injections into the epidural space)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fentanyl analgesia during surgery and nicomorphine afterwards
Number of subjects: 30
Study: 30859858

Group type: EXPERIMENTAL
Intervention: Indoor cycling (20-min time trial)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Outdoor cycling (20-min time trial)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison of indoor vs outdoor cycling
Number of subjects: 20
Study: 28551167

Group type: EXPERIMENTAL
Intervention: Brolucizumab (6 mg/50 μl)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Aflibercept (2 mg/50 μl)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Brolucizumab
Number of subjects: 89

Group type: COMPARATOR
Intervention: Brolucizumab and Aflibercept
Number of subjects: 89
Study: 26418164

Group type: EXPERIMENTAL
Intervention: Weight acceptance
Number of subjects: 394
Study: 23192700

Group type: EXPERIMENTAL
Intervention: Radiotherapy concurrently with weekly cisplatin (30 mg/m²), followed by adjuvant chemotherapy (cisplatin 80 mg/m² on Day 1 and fluorouracil 800 mg/m² on Days 1-5 for 3 cycles)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Radiotherapy concurrently with weekly cisplatin
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 121
Study: 21656149

Group type: EXPERIMENTAL
Intervention: BF-Training
Number of subjects: 24

Group type: COMPARATOR
Intervention: BP-Monitoring
Number of subjects: 24
Study: 19328263

Group type: EXPERIMENTAL
Intervention: It's All About Kids nutrition component (six weekly 30-minute experiential lessons)
Number of subjects: 140
Study: 16772358

Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 66

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 66
Study: 15562177

Group type: EXPERIMENTAL
Intervention: Golf specific warm up programme (performed immediately prior to play and after performing it five times a week for 5 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no warm up programme)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Golf specific warm up programme
Number of subjects: 20
Study: 11591407

Group type: EXPERIMENTAL
Intervention: 1.125 g of Crinone 4% and 8% or 2.25 g of Crinone 8% (containing 45, 90, and 180 mg of P per application)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vaginal P gel Crinone administered to estrogenized women
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Analyzing uterine contraction frequency on accelerated image sequences
Number of subjects: 0
Study: 9022867

Group type: EXPERIMENTAL
Intervention: Regression adjustment for covariates
Number of subjects: 0
Study: 7524044

Group type: EXPERIMENTAL
Intervention: Entex LA tablets (sustained-release, carbomer-based)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Entex PSE tablets (sustained-release, hydroxypropylcellulose-based)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Branded competitor products (sustained-release)
Number of subjects: 15
Study: 3052051

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 13
Study: 4879059

Group type: EXPERIMENTAL
Intervention: Oral dipyridamole
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 103
Study: 31254047

Group type: EXPERIMENTAL
Intervention: Combined hyaluronic acid/chondroitin sulfate (HA/CS)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate (CS)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Comparison between HA/CS and CS
Number of subjects: 68
Study: 28387939

Group type: EXPERIMENTAL
Intervention: Veliparib (ABT-888)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: M8 metabolite
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Veliparib
Number of subjects: 71
Study: 24965306

Group type: EXPERIMENTAL
Intervention: Home enteral nutrition (HEN)
Number of subjects: 456
Study: 22679745

Group type: EXPERIMENTAL
Intervention: Choline-positive neuroprotectors citicoline and choline alfoscerate
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Neuroprotective therapy
Number of subjects: 52
Study: 20726878

Group type: EXPERIMENTAL
Intervention: Proven etiology (identified neurologic disease)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: No identified etiology (no neurologic disease)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Not fully investigated (major information missing)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Etiologies classified as prenatal
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Etiologies classified as perinatal
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Etiologies classified as postnatal
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Other etiologies
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Hypoxic‐ischemic encephalopathy (HIE)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Chromosomal abnormalities
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Malformations
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Stroke
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Tuberous sclerosis complex (TSC)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Periventricular leukomalacia or hemorrhage
Number of subjects: 207
Study: 19089263

Group type: EXPERIMENTAL
Intervention: Dentifrice containing Aloe vera
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fluoridated dentifrice
Number of subjects: 30
Study: 15953322

Group type: EXPERIMENTAL
Intervention: Immediate division of tongue-tie
Number of subjects: 57

Group type: COMPARATOR
Intervention: Intensive lactation consultant support (control)
Number of subjects: 57
Study: 11861668

Group type: EXPERIMENTAL
Intervention: Therapeutic Lifestyle Change (TLC)/Step 2 diet
Number of subjects: 36

Group type: COMPARATOR
Intervention: Western diet
Number of subjects: 36
Study: 10417035

Group type: EXPERIMENTAL
Intervention: Structured pharmaceutical care program (group A)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Standard care (group B)
Number of subjects: 83
Study: 7593525

Group type: EXPERIMENTAL
Intervention: Gonadotrophin‐releasing hormone analogues (GnRHa)
Number of subjects: 140
Study: 2281392

Group type: EXPERIMENTAL
Intervention: Sodium nucleinate (SN)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 7243514

Group type: EXPERIMENTAL
Intervention: Double wall in a forced convection‐heated incubator
Number of subjects: 10
Study: 31676252

Group type: EXPERIMENTAL
Intervention: Screening for diabetic kidney disease (DKD) risk
Number of subjects: 436
Study: 31065958

Group type: EXPERIMENTAL
Intervention: Dual method (DM) of indocyanine green fluorescence (ICG‐F) plus a radioisotope (RI), n = 58
Number of subjects: 130

Group type: COMPARATOR
Intervention: Radioisotope (RI) only, n = 64
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Dual method (DM) of indocyanine green fluorescence (ICG‐F) plus a radioisotope (RI)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Radioisotope (RI) only
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Indocyanine green fluorescence (ICG‐F)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Radioisotope (RI)
Number of subjects: 130
Study: 28706429

Group type: EXPERIMENTAL
Intervention: Reduced-dose sodium phosphate (NaP) tablets with 2 L of clear liquid (30 tablets)
Number of subjects: 200

Group type: COMPARATOR
Intervention: 2 L of polyethylene glycol (PEG)
Number of subjects: 200
Study: 26088013

Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 557
Study: 24238686

Group type: EXPERIMENTAL
Intervention: BITSEA
Number of subjects: 2106

Group type: COMPARATOR
Intervention: ASQ:SE
Number of subjects: 2106

Group type: COMPARATOR
Intervention: KIPPPI
Number of subjects: 2106
Study: 21331516

Group type: EXPERIMENTAL
Intervention: Right ventricle to pulmonary artery shunt, n = 25
Number of subjects: 44

Group type: COMPARATOR
Intervention: Modified Blalock‐Taussig shunt, n = 19
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study: 19352498

Group type: EXPERIMENTAL
Intervention: sulfadoxine‐pyrimethamine (SP)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: chlorproguanil‐dapsone (CD)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: sulfadoxine‐pyrimethamine + amodiaquine (SP+AQ)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: amodiaquine + artesunate (AQ+AS)
Number of subjects: 272
Study: 17532786

Group type: EXPERIMENTAL
Intervention: Lamivudine therapy (group I)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Persistently detectable serum HBV-DNA (group II)
Number of subjects: 221
Study: 17047260

Group type: EXPERIMENTAL
Intervention: Model-based calculation algorithm with a dose kernel scaled for heterogeneities
Number of subjects: 16

Group type: COMPARATOR
Intervention: No model-based calculation algorithm or model-based calculation algorithm with a dose kernel unscaled for heterogeneities
Number of subjects: 16
Study: 12660409

Group type: EXPERIMENTAL
Intervention: Cr (4 x 5 g x day(‐1) x 5 days)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Glucose+Cr (1 g x (‐1) of body mass twice per day)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Exercise+Cr (60 min of daily muscular (repeated‐sprint) exercise)
Number of subjects: 18

Group type: COMPARATOR
Intervention: 0 g x day(‐1) maintenance
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 2 g x day(‐1) maintenance
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 5 g x day(‐1) maintenance
Number of subjects: 18